Skip to content


  • Poster presentation
  • Open Access

Development and evaluation of the oligonucleotide ligation assay (OLA) for the detection of drug resistance mutations in HIV-2 patients on antiretroviral therapy

  • 1, 2Email author,
  • 1,
  • 3,
  • 3,
  • 2,
  • 1,
  • 1 and
  • 2
Retrovirology20063 (Suppl 1) :P29

  • Published:


  • Drug Resistance
  • Nucleoside
  • Treatment Failure
  • Oligonucleotide Probe
  • Resistance Mutation


The naturally resistance of HIV-2 to non-nucleoside reverse transcriptase inhibitors and T-20, as well as its reduced susceptibility to some protease inhibitors makes the nucleoside reverse transcriptase inhibitors (NRTI) crucial in HIV-2 therapy. Hence, early detection of resistance mutations to NRTI is important to explain treatment failures and to guide therapy.

Materials and methods

HIV-2 OLA was developed for the Q151M and M184V mutations using a set of 3 oligonucleotide probes for each mutation. 90 HIV-2 samples from Guinea Bissau, the Gambia and Sweden were amplified, sequenced and evaluated in OLA.


OLA sensitivity was 100% for Q151M and 98% for M184V. Concordance between sequencing and OLA was 99% and 97% for the Q151M and M184V mutations respectively.


OLA was successfully developed for major HIV-2 mutations. Its ease-of-use, economical nature and high concordance with sequencing makes it more appropriate for use in resource-poor settings.

Authors’ Affiliations

Medical Research Council (MRC), Banjul, The Gambia
Department of Microbiology, Institute of Tropical Medicine, Antwerp, Belgium
Department of Virology, Swedish Institute for Infectious Disease Control, Solna, Sweden


© Jallow et al; licensee BioMed Central Ltd. 2006

This article is published under license to BioMed Central Ltd.